Abstract 16666: Osteopontin - A Novel Biomarker for Left Ventricular Hypertrophy and Diastolic Dysfunction
Background and Hypothesis: Osteopontin (OPN) is an extracellular matrix protein that plays an important role in myocardial remodeling. Moreover, our group has previously shown that OPN plasma levels are not only elevated in chronic systolic left heart failure but also predict an adverse prognosis. We now tested the hypothesis whether OPN plasma levels are of diagnostic value in patients with left ventricular hypertrophy (LVH) and diastolic dysfunction due to pressure overload caused by arterial hypertension.
Methods: After exclusion of significant coronary artery disease we included 92 patients with cardiac hypertrophy and hypertensive heart disease, 34 healthy subjects served as controls. OPN plasma levels were determined by ELISA and correlated with clinical symptoms and echocardiographic as well as hemodynamic parameters of LVH and diastolic dysfunction.
Results: Median OPN was significantly elevated in patients with LVH compared to healthy controls (682.2 ng/ml vs. 296.1 ng/ml; p 16 mmHg: 920.3 ng/ml vs. LVEDP ≤ 16 mmHg: 777.8 ng/ml; p<0.01). Additionally, OPN levels showed a positive correlation with LVEDP (r=0.32; p<0.05). Furthermore, higher OPN plasma levels were also associated with progressive enlargement of left atrial size (r=0.53; p<0.01). Consistently, OPN levels were higher in patients with atrial fibrillation (AF) compared to subjects with sinus rhythm (871.0 ng/ml vs. 627.9 ng/ml; p<0.05).
Conclusion: Our data show for the first time that OPN plasma levels are elevated in patients with LVH and diastolic dysfunction. Moreover, increased OPN plasma levels appear to correlate with advanced cardiac remodeling and atrial fibrillation, a known trigger of morbidity and mortality in this patient population. Hence, OPN might be useful as a non-invasive biomarker in patients with LVH and diastolic dysfunction.
- © 2011 by American Heart Association, Inc.